Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Esophageal Neoplasms 2Ovarian Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Cisplatin 38Fluorouracil 37Radiotherapy 33Oxaliplatin 23Paclitaxel 20Irinotecan 18Leucovorin 17Docetaxel 17Capecitabine 10Neoadjuvant Therapy 9Surgical Procedures, Operative 8Cetuximab 8Chemotherapy, Adjuvant 7Radiation 6Carboplatin 6Immunohistochemistry 5Erlotinib Hydrochloride 5Biopsy 5Magnetic Resonance Spectroscopy 4Gene Expression Profiling 4Folfox protocol 4Epirubicin 4Drug Therapy 4pembrolizumab 3Trastuzumab 3Microarray Analysis 3Gefitinib 3Fluorodeoxyglucose F18 3Endoscopy, Digestive System 3ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma Of Esophagus × matuzumab × Clear all
NCT00113581 2014-02-19

Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡